Dr Pooja Gupta

 

Academic details:

• DM (Clinical Pharmacology), All India Institute of Medical Sciences, New Delhi.

• MD (Pharmacology), Maulana Azad Medical College, New Delhi  

• MBBS, Lady Hardinge Medical College, New Delhi

 

Address: Room No 5004, 5^th Floor, Department of Pharmacology, Convergence Block, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029

Areas of Interests: Clinical Pharmacology, oncopharmacology, pharmacovigilance, regulatory pharmacology, pharmacoeconomics, bioethics  

Awards/ Achievements/ Contributions:

• Professor-in-charge, Computer Facility

• AIIMS center coordinator for adverse event monitoring of drugs and medical devices under Pharmacovigilance Program of India and Materiovigilance Program of India

• Member secretary, Institute Ethics Sub-Committee for SAEs in Clinical Trials, AIIMS

• Member and Workshop Coordinator, Working Committee, Clinical research unit, AIIMS, New Delhi

• Member, National Adverse Events Following Immunization (AEFI) Subcommittees (causality assessment and advocacy & media), MoH&FW, GoI

• Member, Subcommittee for medicines under Standing National Committee on Medicines and other Health Care Products, MoH&FW, GoI

• Involved in >15 research projects funded by ICMR, DST, AIIMS, AYUSH, Govt. of India; Guided >20 theses as Guide/Co-guide (PhD/DM/MD/MS/MDS/MSc); and have >40 publications with an h-index of 13.

 

Publications (selected 10):

1. Malhotra S, Kalaivani M, Lodha R, Bakhshi S, Mathur V, Gupta P, Kedia S, Sankar J, Kumar P, Kumar A, Ahuja V, Sinha S, Guleria R, COVID Reinfection AIIMS Consortium. COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India. Lancet Reg Health Southeast Asia. 2022. DOI: 10.1016/j.lansea.2022.100023. 

2. Malhotra S, Kalaivani M, Lodha R, Bakhshi S, Mathur V, Gupta P, Kedia S, Sankar J, Kumar P, Kumar A, Ahuja V, Sinha S, Guleria R, COVID Reinfection AIIMS Consortium. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. JAMA Network Open. 2022;5(1):e2142210. DOI: 10.1001/jamanetworkopen.2021.42210

3. Kajal S, Naeem SS, Gupta P*, Kairo AK, Ahmed A, Verma P, Saini A. Sinonasal mucormycosis and liposomal amphotericin B: A quest for dose optimization. Ind J Pharmacol. 2022;54(2):90-96.

4. Gupta P, Naeem SS, Mohan P, Banerjee A. Is written informed consent cast in iron even during a Pandemic? [Editorial]. Med J Armed Forces India. 2020;76:367-9.

5. Diksha, Gupta P*, Malik PS, Mohan A. A pilot study of oxidative and inflammatory markers as early indicator for response to platinum-based chemotherapy in non-small cell lung cancer patients. J Clin Pharm Ther. 2019; 00: 1– 6. https://doi.org/10.1111/jcpt.13053

6. Gupta P, Anvikar A, Valecha N, Gupta YK. Pharmacovigilance Practices for Better Healthcare Delivery: Knowledge and Attitude Study in the National Malaria Control Programme of India. Malar Res Treat 2014; 2014: 837427. doi:10.1155/2014/837427

7. Gupta P, Mehla J, Gupta YK. Antiobesity effect of Safoof Mohazzil, a Unani herbal formulation, in cafeteria diet induced obesity in rats. Indian J Exp Biol 2012; 50: 776-84.

8. Gupta P, Gupta V, Gupta YK. Anticancer Phase I Clinical Trials in Healthy Volunteers: need for critical consideration. Indian J Pharmacol. 2012; 44: 540-42. 

9. Padhy BM, Gupta P, Gupta YK. Analysis of the compliance of informed consent documents with good clinical practice guideline. Contemp Clin Trials. 2011; 32: 662-666.

10. Gupta P, Roy V, Sethi GR, Mishra TK. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br J Clin Pharmacol. 2008; 65(3): 423-427.

*Corresponding Author